“Oncocytoid Renal Cell Carcinomas After Neuroblastoma” Represent TSC-mutated Eosinophilic Solid and Cystic Renal Cell Carcinomas

The concept of oncocytoid renal cell carcinoma in patients who have survived neuroblastoma as a distinct biologic entity has been controversial since its original description in 1999. This is in part because similar oncocytoid renal cell carcinomas have been described in association with other pediatric cancers, and also because other renal cell carcinoma subtypes (such as MiT family translocation renal cell carcinoma) have been described in children who have survived neuroblastoma. We identified an index case of a child who survived medulloblastoma and developed multifocal bilateral oncocytoid renal cell carcinomas with morphology and immunophenotype compatible with eosinophilic solid and cystic renal cell carcinoma (ESC RCC) and demonstrated that both neoplasms harbored distinctive mutations in the TSC1/TSC2 genes. Remarkably, the child's remaining bilateral multifocal renal neoplasms completely responded to MTOR inhibitor therapy without need for further surgery. To confirm our hypothesis that oncocytoid renal cell carcinomas after childhood cancer represent ESC RCC, we obtained formalin-fixed paraffin-embedded tissue blocks from 2 previously published cases of oncocytoid renal cell carcinoma after neuroblastoma, confirmed that the morphology and immunophenotype was consistent with ESC RCC, and demonstrated that both cases harbored somatic TSC gene mutations. Both expressed markers previously associated with neoplasms harboring TSC gene mutations, glycoprotein nonmetastatic B, and cathepsin K. Of note, one of these patients had 2 ESC RCC which harbored distinctive TSC2 mutations, while the background kidney of the other patient had multiple small cysts lined by similar oncocytoid cells which showed loss of TSC2 protein. We then reviewed 3 of 4 cases from the original 1999 report of oncocytoid renal cell carcinomas after neuroblastoma, found that all 3 demonstrated morphology (including basophilic cytoplasmic stippling) that is characteristic of ESC RCC, showed that all 3 overexpressed glycoprotein nonmetastatic B, and showed that both cases with adequate material demonstrated loss of TSC2 protein and expressed cytokeratin 20 and cathepsin K by immunohistochemistry. In summary, "oncocytoid renal cell carcinomas after neuroblastoma" represent ESC RCC which are often multifocal in patients who have survived childhood cancer, likely representing an incompletely characterized tumor predisposition syndrome. MTOR-targeted therapy represents an effective therapeutic option for such patients to preserve functional nephrons.

[1]  A. Davidoff,et al.  Nephron-sparing surgery for Wilms tumor , 2023, Frontiers in Pediatrics.

[2]  D. Kwiatkowski,et al.  Diagnosis of Mosaic Tuberous Sclerosis Complex Using Next-Generation Sequencing of Subtle or Unusual Cutaneous Findings , 2022, JID innovations : skin science from molecules to population health.

[3]  Mingde Zhao,et al.  TSC/MTOR-associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum , 2022, The American journal of surgical pathology.

[4]  Lisa M Haley,et al.  Xanthomatous Giant Cell Renal Cell Carcinoma , 2022, The American journal of surgical pathology.

[5]  P. Argani,et al.  GPNMB expression identifies TSC1/2/mTOR‐associated and MiT family translocation‐driven renal neoplasms , 2022, The Journal of pathology.

[6]  J. Cheville,et al.  New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia , 2021, Modern Pathology.

[7]  C. Antonescu,et al.  Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC) , 2020, The American journal of surgical pathology.

[8]  A. Sangoi,et al.  Low‐grade oncocytic tumour of kidney (CD117‐negative, cytokeratin 7‐positive): a distinct entity? , 2019, Histopathology.

[9]  S. Dhanasekaran,et al.  Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. , 2018, European urology.

[10]  I. Bottillo,et al.  Identification of a novel TSC2 c.3610G > A, p.G1204R mutation contribute to aberrant splicing in a patient with classical tuberous sclerosis complex: a case report , 2018, BMC Medical Genetics.

[11]  P. Argani,et al.  Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum , 2018, The American journal of surgical pathology.

[12]  Lauren L. Ritterhouse,et al.  Are Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinomas Characterized by Somatic Tuberous Sclerosis Gene Mutations? , 2018, The American journal of surgical pathology.

[13]  P. Argani,et al.  Re‐evaluation of 33 ‘unclassified’ eosinophilic renal cell carcinomas in young patients , 2018, Histopathology.

[14]  J. McKenney,et al.  Eosinophilic solid and cystic renal cell carcinomas have metastatic potential , 2018, Histopathology.

[15]  J. Ginsberg,et al.  Acquired Multiple Cysts of the Kidney in Neuroblastoma Survivors. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  S. Dhanasekaran,et al.  Renal Cell Carcinoma Occurring in Patients With Prior Neuroblastoma: A Heterogenous Group of Neoplasms , 2016, The American journal of surgical pathology.

[17]  R. Varadhan,et al.  Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation , 2016, Leukemia.

[18]  C. Porta,et al.  Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma , 2016, Clinical Cancer Research.

[19]  A. Sangoi,et al.  Eosinophilic, Solid, and Cystic Renal Cell Carcinoma: Clinicopathologic Study of 16 Unique, Sporadic Neoplasms Occurring in Women , 2016, The American journal of surgical pathology.

[20]  Ling Lin,et al.  Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing , 2015, PLoS genetics.

[21]  D. Kwiatkowski,et al.  Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2 , 2015, European Journal of Human Genetics.

[22]  P. Argani,et al.  t(6;11) Renal Cell Carcinoma (RCC): Expanded Immunohistochemical Profile Emphasizing Novel RCC Markers and Report of 10 New Genetically Confirmed Cases , 2014, The American journal of surgical pathology.

[23]  E. Thiele,et al.  Central TSC2 missense mutations are associated with a reduced risk of infantile spasms , 2013, Epilepsy Research.

[24]  R. Ekong,et al.  Functional Assessment of TSC2 Variants Identified in Individuals with Tuberous Sclerosis Complex , 2013, Human mutation.

[25]  E. Levy-Lahad,et al.  PGD for germline mosaicism. , 2012, Reproductive biomedicine online.

[26]  M. Ladanyi,et al.  Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions , 2011, Modern Pathology.

[27]  B. Taillon,et al.  Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex , 2010, Human Genetics.

[28]  S. Tickoo,et al.  Pediatric renal cell carcinoma with oncocytoid features occurring in a child after chemotherapy for cardiac leiomyosarcoma. , 2007, Urology.

[29]  M. Ladanyi,et al.  Translocation carcinomas of the kidney after chemotherapy in childhood. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Mei-Ping Ding,et al.  [Analysis of gene mutation in patients with tuberous sclerosis complex with polymerase chain reaction-single strand conformation polymorphism]. , 2003, Zhonghua er ke za zhi = Chinese journal of pediatrics.

[31]  E. Nanba,et al.  Novel TSC1 and TSC2 mutations in Japanese patients with tuberous sclerosis complex , 2002, Brain and Development.

[32]  A. Hodges,et al.  Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin. , 2001, Human molecular genetics.

[33]  D. Kwiatkowski,et al.  Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. , 2001, American journal of respiratory and critical care medicine.

[34]  G. Kovacs,et al.  Oncocytoid renal cell carcinoma after neuroblastoma: a report of four cases of a distinct clinicopathologic entity. , 1999, The American journal of surgical pathology.

[35]  V. Reuter,et al.  Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm , 2019, The American journal of surgical pathology.

[36]  Marilyn M. Li,et al.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[37]  D. Kwiatkowski,et al.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. , 2001, American journal of human genetics.